Deep Sclerectomy With Trabeculotomy in Advanced GlaucomaNCT07895537
Short-Term Efficacy and Safety of Combined Deep Sclerectomy With Trabeculotomy in Advanced Glaucoma: A Prospective Interventional Study
A study testing Combined Deep Sclerectomy with Trabeculotomy in people with Deep Sclerectomy With Trabeculotomy in Advanced Glaucoma, run by Minia University at 1 site in Egypt.
Trial summary
Brief Summary Glaucoma is a progressive eye disease that can lead to irreversible vision loss if intraocular pressure (IOP) is not adequately controlled. Some patients with advanced glaucoma require surgery when medications and/or laser treatment fail to achieve the desired pressure reduction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Deep Sclerectomy With Trabeculotomy in Advanced Glaucoma
- What is being tested?
- Combined Deep Sclerectomy with Trabeculotomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Sep 2025to 5 Oct 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older.
- Established diagnosis of glaucoma requiring surgical intraocular pressure reduction.
- Advanced glaucomatous optic neuropathy, defined by structural and/or functional criteria, preferably including reliable visual field testing demonstrating advanced loss according to the Hodapp-Parrish-Anderson classification when feasible.
- Intraocular pressure above the individualized target despite maximally tolerated topical antiglaucoma therapy and/or previous laser treatment, or documented glaucoma progression despite apparently controlled intraocular pressure.
- Open or sufficiently accessible anterior chamber angle anatomy suitable for the planned trabeculotomy.
- Ability to understand the study procedures and provide written informed consent.
- Willingness and ability to attend all scheduled postoperative follow-up visits.
Who cannot join
- Previous glaucoma filtering surgery in the study eye that substantially alters the intended surgical site.
- Active ocular inflammation or uncontrolled uveitis.
- Active infectious ocular disease.
- Significant corneal opacity preventing adequate surgical visualization or reliable intraocular pressure measurement.
- Severe ocular surface disease interfering with postoperative assessment.
- Previous major conjunctival surgery in the planned filtration area.
Show all 11Show fewer
- Neovascular glaucoma requiring a different surgical strategy.
- Uncontrolled active retinal disease requiring urgent vitreoretinal intervention.
- Severe ocular trauma or extensive conjunctival scarring.
- Inability to provide informed consent or comply with the follow-up schedule.
- Any systemic or ocular condition judged by the investigator to make participation inappropriate or unsafe.
Trial locations and contacts
1 site in 1 country.
About this study
Brief Summary
Glaucoma is a progressive eye disease that can lead to irreversible vision loss if intraocular pressure (IOP) is not adequately controlled. Some patients with advanced glaucoma require surgery when medications and/or laser treatment fail to achieve the desired pressure reduction.
Read more
This prospective, single-center interventional study aims to evaluate the short-term effectiveness and safety of a combined glaucoma surgery involving deep sclerectomy, trabeculotomy. The study will include 20 eyes of eligible adult patients with advanced glaucoma who require surgical treatment to lower intraocular pressure.
All participants will undergo the planned surgical procedure and receive postoperative care according to a standardized protocol. Follow-up examinations will be performed on the first postoperative day, at one week, and at one, three, and six months after surgery.
The primary outcome will be the change in intraocular pressure from baseline to three months after surgery. Secondary outcomes will include changes in the number of glaucoma medications required, visual acuity, surgical success, the need for additional treatment, and the occurrence of intraoperative or postoperative complications.
The findings are expected to provide information about the short-term effectiveness and safety of this modified surgical technique in patients with advanced glaucoma. As a single-center study without a comparison group, the results will be interpreted in the context of its design and sample size.
Read the detailed description
Detailed Description
Glaucoma is a chronic, progressive optic neuropathy characterized by structural damage to the optic nerve and corresponding visual field loss. In patients with advanced glaucoma, achieving adequate intraocular pressure (IOP) control is particularly important because further disease progression may result in substantial and irreversible visual impairment. When medical and/or laser therapy fails to achieve the individualized target IOP, surgical intervention may be required.
Deep sclerectomy is a non-penetrating glaucoma filtration procedure intended to improve aqueous humor outflow while avoiding deliberate full-thickness entry into the anterior chamber. Trabeculotomy enhances aqueous drainage by opening the trabecular meshwork and improving access to Schlemm's canal. Combining these procedures may provide complementary mechanisms for lowering IOP.
The present prospective, single-center interventional study will evaluate the short-term efficacy and safety of a modified surgical technique combining deep sclerectomy, trabeculotomy in patients with advanced glaucoma who require surgical IOP reduction.
The study will recruit 20 eyes of eligible adult patients with advanced glaucoma at the Department of Ophthalmology, Faculty of Medicine, Al-Azhar University. Participants will undergo a standardized preoperative ophthalmic assessment, including visual acuity measurement, Goldmann applanation tonometry, slit-lamp examination, gonioscopy, optic nerve assessment, and visual field testing when feasible.
All procedures will be performed by the same experienced glaucoma surgeon using a standardized surgical technique. The procedure will include creation of a superficial scleral flap, deep scleral dissection with exposure of the trabeculo-Descemet membrane, trabeculotomy, and placement of a sub-flap mattress suture designed to maintain controlled separation between the superficial scleral flap and the underlying scleral bed. The intended purpose of this modification is to regulate the intrascleral space while allowing continued aqueous percolation. The conjunctiva will be closed watertight.
Postoperative management will follow a standardized regimen consisting of topical antibiotic treatment, topical corticosteroids with tapering according to clinical findings, and lubricants as required. Antiglaucoma medications and additional interventions will be used when clinically indicated according to the treating surgeon's assessment and the study protocol.
Participants will be followed on postoperative day 1, at week 1, and at months 1, 3, and 6. Assessments will include IOP, best-corrected visual acuity, slit-lamp findings, anterior chamber status, filtering bleb appearance, antiglaucoma medication requirements, and postoperative complications. Additional glaucoma medication, laser treatment, or surgery will be documented when required.
The primary outcome is the change in IOP from baseline to three months after surgery. Secondary outcomes include percentage IOP reduction, change in the number of antiglaucoma medications, complete and qualified surgical success, change in visual acuity, time to surgical failure, need for additional intervention, and the frequency and severity of intraoperative and postoperative complications.
Continuous variables will be summarized according to their distributions. Paired Student's t-tests or Wilcoxon signed-rank tests will be used, as appropriate, to compare preoperative and postoperative measurements. Categorical variables will be summarized as frequencies and percentages.
The study is intended to provide preliminary evidence regarding the short-term efficacy and safety of this modified surgical technique. Because it is a single-center interventional study with a planned sample of 20 eyes and no comparison group, the findings will be interpreted cautiously and will not establish superiority over other glaucoma procedures.
- Being tested
- Combined Deep Sclerectomy with Trabeculotomy
- Keywords
- Advanced glaucoma; Deep sclerectomy; Trabeculotomy; Intraocular pressure; Glaucoma surgery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Combined Deep Sclerectomy with TrabeculotomyProcedure or surgery
Participants with advanced glaucoma requiring surgical intraocular pressure reduction will undergo combined deep sclerectomy and trabeculotomy . The procedure involves creation of superficial and deep scleral flaps, removal of deep scleral tissue to expose the trabeculo-Descemet membrane, trabeculotomy to enhance aqueous outflow, and placement of a sub-flap mattress suture to maintain controlled separation between the superficial scleral flap and the underlying scleral bed. The conjunctiva will be closed watertight. All participants will receive standardized postoperative treatment and follow-up examinations for six months. The intervention will be evaluated for its effect on intraocular pressure, antiglaucoma medication requirements, visual acuity, surgical success, and postoperative complications.
| Study group | Role | What they receive |
|---|---|---|
| Combined Deep Sclerectomy with Trabeculotomy and Sub-Flap Mattress Suture | Experimental | Participants with advanced glaucoma requiring surgical intraocular pressure reduction will undergo combined deep sclerectomy and trabeculotomy . The procedure is intended to reduce intraocular pressure by enhancing aqueous humor outflow while maintaining controlled separation of the superficial scleral flap from the underlying scleral bed. All participants will receive standardized postoperative treatment and follow-up for six months to assess intraocular pressure, antiglaucoma medication requirements, visual acuity, surgical success, and postoperative complications Receives: Procedure: Combined Deep Sclerectomy with Trabeculotomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Intraocular Pressure from Baseline to 3 Months After Surger
he change in intraocular pressure (IOP), measured in mmHg using Goldmann applanation tonometry, from the preoperative baseline measurement to 3 months after combined deep sclerectomy with trabeculotomy and sub-flap mattress suture. The change will be calculated as the 3-month postoperative IOP minus the baseline IOP.
Measured: Baseline (preoperative) to 3 months after surger
Secondary outcomes (4)
Change in Antiglaucoma Medication Requirements
Change in the number of antiglaucoma medications used by participants from the preoperative baseline to postoperative follow-up visits.
Measured: Baseline to 1, 3, and 6 months after surgery.
Percentage Reduction in Intraocular Pressure
Percentage reduction in intraocular pressure (IOP) from baseline, calculated as [(baseline IOP - postoperative IOP) / baseline IOP] × 100.
Measured: Baseline to 1, 3, and 6 months after surgery..
Percentage Reduction in Intraocular Pressure
Percentage reduction in intraocular pressure (IOP) from baseline, calculated as [(baseline IOP - postoperative IOP) / baseline IOP] × 100.
Measured: Baseline to 1, 3, and 6 months after surgery.
Proportion of Eyes Achieving Complete and Qualified Surgical Success
The proportion of eyes meeting the predefined criteria for complete and qualified surgical success. Complete success is defined as IOP within the prespecified target range without antiglaucoma medications or additional glaucoma surgery. Qualified success is defined as IOP within the prespecified target range with or without antiglaucoma medications and without additional glaucoma surgery.
Measured: 3 and 6 months after surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start15 Sep 2025
- Primary completion5 Mar 2026
- Study completion5 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Deep Sclerectomy With Trabeculotomy in Advanced GlaucomaStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mahmoud Ramadan, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07895537
- Sponsor's protocol ID
- OPH026/10/247/9/2025
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared because of patient confidentiality and privacy considerations. The study results will be disseminated in aggregate form. Requests for access to anonymized data may be considered by the principal investigator, subject to institutional policies, ethical approval, and applicable data protection requirements.
Publications
Kotb MS, El Gharbawy SA, Abdelrahman AM, Makled HS. Sutureless versus conventional deep sclerectomy for management of open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2023 Apr;261(4):1083-1090. doi: 10.1007/s00417-022-05910-4. Epub 2022 Nov 26.
PubMed 36435917Sharifipour F, Yazdani S, Asadi M, Saki A, Nouri-Mahdavi K. Modified Deep Sclerectomy for the Surgical Treatment of Glaucoma. J Ophthalmic Vis Res. 2019 Apr-Jun;14(2):144-150. doi: 10.4103/jovr.jovr_228_17.
PubMed 31114650Luke C, Dietlein TS, Luke M, Konen W, Krieglstein GK. A prospective trial of phaco-trabeculotomy combined with deep sclerectomy versus phaco-trabeculectomy. Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1163-8. doi: 10.1007/s00417-008-0821-8. Epub 2008 Apr 15.
PubMed 18414886
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Short-Term Efficacy and Safety of Combined Deep Sclerectomy With Trabeculotomy in Advanced Glaucoma: A Prospective Interventional Study
- ClinicalTrials.gov ID
- NCT07895537
- Acronym / sponsor ID
- OPH026/10/247/9/2025
- Keywords
- Advanced glaucoma; Deep sclerectomy; Trabeculotomy; Intraocular pressure; Glaucoma surgery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 15 Sep 2025 (actual)
- Primary completion
- 5 Mar 2026 (actual)
- Study completion
- 5 Oct 2026 (actual)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brief Summary
Glaucoma is a progressive eye disease that can lead to irreversible vision loss if intraocular pressure (IOP) is not adequately controlled. Some patients with advanced glaucoma require surgery when medications and/or laser treatment fail to achieve the desired pressure reduction.
This prospective, single-center interventional study aims to evaluate the short-term effectiveness and safety of a combined glaucoma surgery involving deep sclerectomy, trabeculotomy. The study will include 20 eyes of eligible adult patients with advanced glaucoma who require surgical treatment to lower intraocular pressure.
All participants will undergo the planned surgical procedure and receive postoperative care according to a standardized protocol. Follow-up examinations will be performed on the first postoperative day, at one week, and at one, three, and six months after surgery.
The primary outcome will be the change in intraocular pressure from baseline to three months after surgery. Secondary outcomes will include changes in the number of glaucoma medications required, visual acuity, surgical success, the need for additional treatment, and the occurrence of intraoperative or postoperative complications.
The findings are expected to provide information about the short-term effectiveness and safety of this modified surgical technique in patients with advanced glaucoma. As a single-center study without a comparison group, the results will be interpreted in the context of its design and sample size.
Detailed description
Detailed Description
Glaucoma is a chronic, progressive optic neuropathy characterized by structural damage to the optic nerve and corresponding visual field loss. In patients with advanced glaucoma, achieving adequate intraocular pressure (IOP) control is particularly important because further disease progression may result in substantial and irreversible visual impairment. When medical and/or laser therapy fails to achieve the individualized target IOP, surgical intervention may be required.
Deep sclerectomy is a non-penetrating glaucoma filtration procedure intended to improve aqueous humor outflow while avoiding deliberate full-thickness entry into the anterior chamber. Trabeculotomy enhances aqueous drainage by opening the trabecular meshwork and improving access to Schlemm's canal. Combining these procedures may provide complementary mechanisms for lowering IOP.
The present prospective, single-center interventional study will evaluate the short-term efficacy and safety of a modified surgical technique combining deep sclerectomy, trabeculotomy in patients with advanced glaucoma who require surgical IOP reduction.
The study will recruit 20 eyes of eligible adult patients with advanced glaucoma at the Department of Ophthalmology, Faculty of Medicine, Al-Azhar University. Participants will undergo a standardized preoperative ophthalmic assessment, including visual acuity measurement, Goldmann applanation tonometry, slit-lamp examination, gonioscopy, optic nerve assessment, and visual field testing when feasible.
All procedures will be performed by the same experienced glaucoma surgeon using a standardized surgical technique. The procedure will include creation of a superficial scleral flap, deep scleral dissection with exposure of the trabeculo-Descemet membrane, trabeculotomy, and placement of a sub-flap mattress suture designed to maintain controlled separation between the superficial scleral flap and the underlying scleral bed. The intended purpose of this modification is to regulate the intrascleral space while allowing continued aqueous percolation. The conjunctiva will be closed watertight.
Postoperative management will follow a standardized regimen consisting of topical antibiotic treatment, topical corticosteroids with tapering according to clinical findings, and lubricants as required. Antiglaucoma medications and additional interventions will be used when clinically indicated according to the treating surgeon's assessment and the study protocol.
Participants will be followed on postoperative day 1, at week 1, and at months 1, 3, and 6. Assessments will include IOP, best-corrected visual acuity, slit-lamp findings, anterior chamber status, filtering bleb appearance, antiglaucoma medication requirements, and postoperative complications. Additional glaucoma medication, laser treatment, or surgery will be documented when required.
The primary outcome is the change in IOP from baseline to three months after surgery. Secondary outcomes include percentage IOP reduction, change in the number of antiglaucoma medications, complete and qualified surgical success, change in visual acuity, time to surgical failure, need for additional intervention, and the frequency and severity of intraoperative and postoperative complications.
Continuous variables will be summarized according to their distributions. Paired Student's t-tests or Wilcoxon signed-rank tests will be used, as appropriate, to compare preoperative and postoperative measurements. Categorical variables will be summarized as frequencies and percentages.
The study is intended to provide preliminary evidence regarding the short-term efficacy and safety of this modified surgical technique. Because it is a single-center interventional study with a planned sample of 20 eyes and no comparison group, the findings will be interpreted cautiously and will not establish superiority over other glaucoma procedures.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Combined Deep Sclerectomy with Trabeculotomy and Sub-Flap Mattress Suture | Experimental | Procedure: Combined Deep Sclerectomy with TrabeculotomyParticipants with advanced glaucoma requiring surgical intraocular pressure reduction will undergo combined deep sclerectomy and trabeculotomy . The procedure is intended to reduce intraocular pressure by enhancing aqueous humor outflow while maintaining controlled separation of the superficial scleral flap from the underlying scleral bed. All participants will receive standardized postoperative treatment and follow-up for six months to assess intraocular pressure, antiglaucoma medication requirements, visual acuity, surgical success, and postoperative complications |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age 18 years or older.
- Established diagnosis of glaucoma requiring surgical intraocular pressure reduction.
- Advanced glaucomatous optic neuropathy, defined by structural and/or functional criteria, preferably including reliable visual field testing demonstrating advanced loss according to the Hodapp-Parrish-Anderson classification when feasible.
- Intraocular pressure above the individualized target despite maximally tolerated topical antiglaucoma therapy and/or previous laser treatment, or documented glaucoma progression despite apparently controlled intraocular pressure.
- Open or sufficiently accessible anterior chamber angle anatomy suitable for the planned trabeculotomy.
Key exclusion criteria (11 listed)
- Previous glaucoma filtering surgery in the study eye that substantially alters the intended surgical site.
- Active ocular inflammation or uncontrolled uveitis.
- Active infectious ocular disease.
- Significant corneal opacity preventing adequate surgical visualization or reliable intraocular pressure measurement.
- Severe ocular surface disease interfering with postoperative assessment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Combined Deep Sclerectomy with TrabeculotomyParticipants with advanced glaucoma requiring surgical intraocular pressure reduction will undergo combined deep sclerectomy and trabeculotomy . The procedure involves creation of superficial and deep scleral flaps, removal of deep scleral tissue to expose the trabeculo-Descemet membrane, trabeculotomy to enhance aqueous outflow, and placement of a sub-flap mattress suture to maintain controlled separation between the superficial scleral flap and the underlying scleral bed. The conjunctiva will be closed watertight. All participants will receive standardized postoperative treatment and follow-up examinations for six months. The intervention will be evaluated for its effect on intraocular pressure, antiglaucoma medication requirements, visual acuity, surgical success, and postoperative complications. | Procedure or surgery | Combined Deep Sclerectomy with Trabeculotomy and Sub-Flap Mattress Suture |
Primary outcome
Change in Intraocular Pressure from Baseline to 3 Months After Surger
Time frame: Baseline (preoperative) to 3 months after surger
he change in intraocular pressure (IOP), measured in mmHg using Goldmann applanation tonometry, from the preoperative baseline measurement to 3 months after combined deep sclerectomy with trabeculotomy and sub-flap mattress suture. The change will be calculated as the 3-month postoperative IOP minus the baseline IOP.
4 secondary outcomes
Change in Antiglaucoma Medication Requirements
Time frame: Baseline to 1, 3, and 6 months after surgery.
Percentage Reduction in Intraocular Pressure
Time frame: Baseline to 1, 3, and 6 months after surgery..
Percentage Reduction in Intraocular Pressure
Time frame: Baseline to 1, 3, and 6 months after surgery.
Proportion of Eyes Achieving Complete and Qualified Surgical Success
Time frame: 3 and 6 months after surgery.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Results publication: PubMed 36435917Kotb MS, El Gharbawy SA, Abdelrahman AM, Makled HS. Sutureless versus conventional deep sclerectomy for management of open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2023 Apr;261(4):1083-1090. doi: 10.1007/s00417-022-05910-4. Epub 2022 Nov 26.
- Results publication: PubMed 31114650Sharifipour F, Yazdani S, Asadi M, Saki A, Nouri-Mahdavi K. Modified Deep Sclerectomy for the Surgical Treatment of Glaucoma. J Ophthalmic Vis Res. 2019 Apr-Jun;14(2):144-150. doi: 10.4103/jovr.jovr_228_17.
- Results publication: PubMed 18414886Luke C, Dietlein TS, Luke M, Konen W, Krieglstein GK. A prospective trial of phaco-trabeculotomy combined with deep sclerectomy versus phaco-trabeculectomy. Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1163-8. doi: 10.1007/s00417-008-0821-8. Epub 2008 Apr 15.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared because of patient confidentiality and privacy considerations. The study results will be disseminated in aggregate form. Requests for access to anonymized data may be considered by the principal investigator, subject to institutional policies, ethical approval, and applicable data protection requirements.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Combined Deep Sclerectomy with Trabeculotomy in people with Deep Sclerectomy With Trabeculotomy in Advanced Glaucoma, run by Minia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Intraocular Pressure from Baseline to 3 Months After Surger (time frame: Baseline (preoperative) to 3 months after surger). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07895537, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.